Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study
Nutrients · 2026
DOI: 10.3390/nu18101569 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2026. Verfasst von Christian Lambiase und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Quality of Life, gamma-Aminobutyric Acid, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Recent studies have shown that GABA reduces visceral hypersensitivity and improves intestinal permeability in a post-inflammatory irritable bowel syndrome (IBS) rat model. We aimed to assess the efficacy of a GABA-based supplement in IBS patients with diarrhea (IBS-D), focusing on symptoms relief, quality-of-life improvement, mucosal barrier function, systemic microinflammation and gut microbiota.
Methods
In this double-blind, placebo-controlled, crossover study, 20 IBS-D patients were randomized to receive GABA or placebo for two four-week treatment periods separated by a two-week washout. Efficacy was assessed using IBS Symptom Severity Score (IBS-SSS) and Short-Form Health Survey-36 (SF-36). Circulating levels of lipopolysaccharide-binding protein (LBP), Tumor Necrosis Factor-α (TNF-α) and interleukin (IL)-1β were measured before and after each treatment.
Results
Eighteen patients completed the study. A clinical response (≥50-point reduction in IBS-SSS) was observed in 66.7% of patients during GABA treatment versus 33.3% with placebo. GABA produced a significant reduction in the IBS-SSS total score (p = 0.02) and in the bowel satisfaction item of the questionnaire (p = 0.02). Regarding quality of life, GABA significantly improved the “Emotional limitation” domain compared with placebo (p = 0.009). GABA treatment also led to a decrease in circulating LBP (p = 0.06) and IL-1β (p = 0.02) levels compared to placebo, although only the reduction in IL-1β reached statistical significance. In contrast, no substantial remodeling of the gut microbiota was observed.
Conclusions
In this pilot study, GABA treatment led to a significant improvement in IBS-D symptoms compared with placebo and was also more effective in enhancing emotional wellbeing. GABA appeared to have a possible effect on intestinal permeability indirectly assessed through LBP, consistent with preclinical findings, and significantly reduced systemic inflammation. GABA may represent a promising therapeutic option for IBS, deserving further investigation in larger clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
- Regional Center for Functional and Motility Digestive Disorders, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.
- Gastroenterology Unit, Annunziata Hospital, Azienda Ospedaliera di Cosenza (AOCS), 87100 Cosenza, Italy.
- Retrovirus Center, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
- Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
- Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
ORCID-Profile: Francesco Rettura, Andrea Bottari, Fabio Filippini, Stefano Salvadori, Letizia Campigli, Matteo Fornai, Nicola de Bortoli, Massimo Bellini
Zitieren
APA
Lambiase, C., Cancelli, L., Tedeschi, R., Grosso, A., Rettura, F., Salemmo, R., Bottari, A., Filippini, F., Salvadori, S., Valdiserra, G., Campigli, L., Antonioli, L., Fornai, M., de Bortoli, N., & Bellini, M. (2026). Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study. Nutrients. https://doi.org/10.3390/nu18101569
Vancouver
Lambiase C, Cancelli L, Tedeschi R, Grosso A, Rettura F, Salemmo R, et al. Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study. Nutrients. 2026. doi:10.3390/nu18101569
BibTeX
@article{Lambiase2026,
author = {Lambiase, Christian and Cancelli, Lorenzo and Tedeschi, Riccardo and Grosso, Antonio and Rettura, Francesco and Salemmo, Rebecca and Bottari, Andrea and Filippini, Fabio and Salvadori, Stefano and Valdiserra, Giulia and Campigli, Letizia and Antonioli, Luca and Fornai, Matteo and de Bortoli, Nicola and Bellini, Massimo},
title = {Effects of γ-Aminobutyric Acid (GABA) Supplementation on Symptoms, Quality of Life, Intestinal Permeability, Systemic Inflammation and Gut Microbiota in Patients with IBS-D: A Randomized, Double Blind, Placebo-Controlled, Crossover Pilot Study},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18101569}
}
EUVIMED